Larazotide Safety and Adverse Events: What Studies Report

What the published record actually contains

Larazotide acetate, also written as AT1001, is a synthetic octapeptide studied as a zonulin antagonist, and a 2025 review of zonulin biology described zonulin-directed agents such as larazotide in the context of tight junction regulation and intestinal barrier function (PMID 39252622). The bulk of the human safety record sits in placebo-controlled trials in adults with celiac disease, including two gluten-challenge studies (PMID 22825365, PMID 23163616), a randomized trial in patients with persistent symptoms despite a gluten-free diet (PMID 25683116), and a systematic review and meta-analysis that pooled randomized controlled trials of larazotide acetate in celiac disease (PMID 34339872). Outside celiac disease, the published material is narrower: a case series and a translational study describing adjunctive use in children with multisystem inflammatory syndrome (PMID 35211683, PMID 40737433), plus a computational docking analysis with no human participants at all (PMID 33520943).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition, a medication, or an investigational compound. Nothing here describes a regimen, and no reader should infer one from the doses that researchers happened to study.

Adverse Events in Celiac Disease Trials: What Studies Report

Pooled randomized trial data

The most direct roll-up of tolerability comes from the systematic review and meta-analysis of randomized controlled trials, in which the researchers reported that rates of adverse events did not differ significantly between larazotide acetate and placebo across the pooled trials, while symptom improvement was associated with the 0.5 mg three-times-daily dose (PMID 34339872). That pooled comparison is the single most frequently cited safety statement about the compound, and it is a comparison of event rates in short randomized trials rather than a demonstration that no adverse effects occur.

Gluten-challenge studies

In the randomized, double-blind study designed to test whether larazotide acetate could limit activation of celiac disease during a gluten challenge, the study administered larazotide acetate at 1 mg, 4 mg or 8 mg three times daily against placebo in adults with celiac disease (PMID 22825365). A second randomised, placebo-controlled gluten-challenge study likewise evaluated larazotide acetate at 1 mg, 4 mg and 8 mg three times daily in adults with coeliac disease, with gastrointestinal symptoms and intestinal permeability among the measured outcomes (PMID 23163616). Because these designs deliberately exposed participants to gluten, symptom reports in both arms reflect the challenge as well as the study drug — a confounder the researchers built into the comparison by including placebo groups (PMID 23163616).

Persistent symptoms on a gluten-free diet

The randomized controlled trial in patients with persistent symptoms of celiac disease despite a gluten-free diet evaluated larazotide acetate at 0.5 mg, 1 mg and 2 mg three times daily over a 12-week treatment period, with the 0.5 mg dose meeting the trial's primary symptom endpoint relative to placebo (PMID 25683116). Notably, that trial did not report a straightforward dose–response, and the pooled analysis reached the same conclusion about the lowest dose studied (PMID 34339872). For safety interpretation, this matters: the doses that produced the reported symptom signal were the low ones, so tolerability observations from the higher-dose gluten-challenge arms (PMID 22825365) are not interchangeable with those from the 0.5 mg arm (PMID 25683116).

Doses and durations that appear in the published trials

The table reproduces what researchers studied. It is not a schedule, and the fact that a dose appeared in a trial says nothing about its suitability for any individual.

Paediatric and Critical Care Reports: What Studies Report

A 2022 case series described larazotide (AT1001) used as an adjuvant treatment in children with multisystem inflammatory syndrome, framing the rationale around zonulin-mediated barrier dysfunction (PMID 35211683). A 2025 translational study reported viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide (PMID 40737433). Case series and small treated cohorts are, by design, poorly suited to detecting adverse effects: without randomisation and a control arm, an event observed during treatment cannot be separated from the underlying illness, which in this population was severe (PMID 35211683). Readers comparing paediatric reports with adult celiac trials should note that the adult tolerability comparison rests on randomized data (PMID 34339872) while the paediatric material does not (PMID 35211683).

Why route of administration shapes the safety discussion

The trials cited here used oral administration in adults with celiac disease (PMID 25683116), consistent with the way reviews of celiac therapeutics describe larazotide as a luminally acting candidate among non-dietary approaches (PMID 41010485). A 2025 review of zonulin in chronic inflammatory disorders placed such agents within tight junction and barrier-function regulation rather than systemic immunosuppression (PMID 39252622). That mechanistic framing is often used to explain why trial safety comparisons looked similar to placebo (PMID 34339872), but mechanism is an explanation, not evidence; the evidence for tolerability is the randomized comparison itself (PMID 34339872).

Computational work carries no safety information

An in silico analysis reported potential anti-SARS-CoV-2 main protease activity for larazotide acetate using molecular modelling (PMID 33520943). Docking studies of that kind involve no humans, no animals and no dosing, so they contribute nothing to an adverse-event profile (PMID 33520943). Computational hits are frequently mistaken for pharmacological findings in secondary summaries, and this page treats them as hypothesis-generating only.

What the literature summarised here does not establish

Several gaps are plain absences rather than reassuring silences:

• No long-term human safety data. The longest treatment period among the trials cited here was the 12-week period in the persistent-symptoms trial (PMID 25683116); nothing in this citation set reported multi-year exposure.
• No healthy-volunteer tolerability series. The randomized evidence pooled in the meta-analysis came from trials in celiac disease populations (PMID 34339872), not from people without the condition.
• No randomized paediatric safety comparison. The paediatric material in this set was a case series (PMID 35211683) and a translational treated-cohort report (PMID 40737433).
• No pregnancy, lactation, hepatic or renal impairment data appear anywhere in the papers summarised on this page.
• No interaction studies. Reviews of celiac treatment options discussed larazotide alongside enzyme, microbial and immune-directed candidates without reporting drug-interaction data (PMID 41769533).

How reviews describe larazotide's development status

A 2025 update on current treatments for celiac disease discussed larazotide among investigational non-dietary options while describing gluten restriction as the existing mainstay of management (PMID 41010485). A 2026 narrative review of microbial, fungal and plant-derived interventions similarly positioned barrier-directed and enzymatic candidates as investigational adjuncts rather than replacements for dietary management (PMID 41769533). Larazotide is not an approved drug product; peptide material sold for laboratory work is typically labelled research-use-only and is not a medicine. Regulatory status can change, and this paragraph is descriptive rather than legal advice.

How to read the tolerability claim without overreading it

Three limits apply to the central statement that adverse event rates did not differ significantly from placebo in pooled randomized trials (PMID 34339872). First, the pooled sample sizes were those of phase-2-scale celiac trials, which are underpowered for uncommon events (PMID 34339872). Second, the gluten-challenge designs introduced deliberate symptom provocation in both arms, so symptom-type adverse events are entangled with the challenge itself (PMID 22825365, PMID 23163616). Third, the dose that carried the reported efficacy signal — 0.5 mg three times daily — was studied in a single 12-week trial (PMID 25683116) and confirmed as the effective dose in the pooled analysis (PMID 34339872), so safety at that dose rests on a comparatively thin exposure base.

Readers who want the mechanism, trial history and endpoint design explained step by step, rather than the adverse-event record summarised, can work through the larazotide course; this page deliberately stays with what the safety literature reports and where it is silent. Any decision about a medical condition belongs with a licensed clinician, not with a literature summary.

References

• Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials (Clinics and Research in Hepatology and Gastroenterology, 2022)
• Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial (Gastroenterology, 2015)
• A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge (The American Journal of Gastroenterology, 2012)
• Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study (Alimentary Pharmacology & Therapeutics, 2013)
• Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series (Critical Care Explorations, 2022)
• Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide (Science Translational Medicine, 2025)
• Elucidating the Significance of Zonulin in the Pathogenesis of Chronic Inflammatory Disorders: Emphasis on Intestinal Barrier Function and Tight Junction Regulation (Current Medicinal Chemistry, 2025)
• Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments (Nutrients, 2025)
• Integrated Role of Microbial, Fungal, and Plant-Derived Interventions in the Management of Celiac Disease: A Narrative Review (Cureus, 2026)
• In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate (Frontiers in Chemistry, 2020)